
Novo Nordisk has more than doubled its goal for the sales of its obesity drugs, now aiming for over DKK 25bn (USD 3.7bn) in sales in 2025.
Executive Vice President for Commercial Strategy and Corporate Affairs Camilla Sylvest revealed this at the company’s capital markets day on March 3.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app